The February 9 2026 edition of Pulmonary Hypertension News reports that enrollment has been completed in under a year for the PHocus Phase 2 clinical trial testing mosliciguat, a once-daily inhaled therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD)—a condition where current treatment options remain limited and often poorly tolerated. Developed by Pulmovant, mosliciguat targets soluble guanylate cyclase (sGC) directly in the lungs to lower pulmonary blood pressure and improve blood flow while minimizing effects on the rest of the body.
The study is evaluating safety and effectiveness in approximately 120 patients across 18 US sites over 24 weeks, with top-line results expected later this year. Earlier Phase 1b data showed a mean reduction in pulmonary vascular resistance of up to 38%—one of the largest decreases reported in pulmonary hypertension trials to date—suggesting promising potential for this new therapeutic approach.
In addition to PHocus, mosliciguat is also being tested in another Phase 2 study, known as PHactor (NCT07333183). That study is evaluating the safety and tolerability of mosliciguat when used in combination with inhaled treprostinil, a therapy marketed in the U.S. as Tyvaso, Tyvaso DPI, and Yutrepia.
Read more at this link on Pulmonary Hypertension News
Read Pulmovant’s press release here